Full text is available at the source.
Abstract
Essence
Mazdutide became a China-approved dual GcgR and GLP-1R agonist for long-term weight management and later T2D glycaemic control.
Evidence
This first-approval review summarizes mazdutide development milestones, including China approvals for adults with BMI >= 28 kg/m2 or BMI >= 24 kg/m2 with a weight-related comorbidity, and for adults with T2D.
Caveat
The article is a regulatory milestone summary, not an independent comparative trial or long-term safety analysis.
Simplified
GLP-1 Therapies